International Flavors & Fragrances Inc. (IFF) SEC Filings & Earnings Calls
EquiReason read 12 International Flavors & Fragrances Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — IFF reported Q2 2026 results: sales +2% reported (+6% comparable currency neutral), gross margin +80bps, operating profit +11%, and announced $2.5B share repurchase authorization..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 24.0B
- P/E TTM
- 82.6
- Dividend yield
- 1.7%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QIFF reported Q2 2026 results: sales +2% reported (+6% comparable currency neutral), gross margin +80bps, operating profit +11%, and announced $2.5B share repurchase authorization.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $1.95B | +2% y/y |
| Gross margin · Q2-2026 | 43.7% | |
| Operating profit · Q2-2026 | $158M | +11% y/y |
| Operating cash flow · H1-2026 | $679M | +85% y/y |
| Capital expenditure · H1-2026 | $301M |
Guidance
Capital spending expected to be approximately 6.0% of total company sales in 2026, up from approximately 5.5% in 2025
Management reaffirmed outlook with capex guidance increase to 6.0% of sales, indicating confidence in demand and investment.
Risks flagged
Regulatory costs pressure
“The increase in S&A expenses was primarily driven by higher incentive compensation expense and regulatory costs.” · word for word
Divestiture execution risk
“On May 29, 2026, we announced that we entered into a definitive agreement to divest our Food Ingredients disposal group.” · word for word
4 Aug 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Divestiture execution risk; regulatory approvals needed.
“Closing subject to regulatory approvals and customary conditions.”
4 Aug 20268-K · 2.02, 8.01Sales $1.95B (+2% y/y); Adjusted Operating EBITDA $408M; Adjusted Operating EBITDA Margin 20.9; Guidance: Full year 2026 guidance on continuing ops basisearningsopen
Figures in the filing · each found in the filing text
| Sales · continuing_operations · Q2-2026 | $1.95B | +2% y/y |
| Adjusted Operating EBITDA · continuing_operations · Q2-2026 | $408M | |
| Adjusted Operating EBITDA Margin · continuing_operations · Q2-2026 | 20.9% |
Guidance
Full year 2026 guidance on continuing ops basis
Guidance consistent with previous; underlying performance unchanged.
Risks flagged
Divestiture execution risk; stranded cost elimination needed.
“Stranded costs to be eliminated; regulatory approvals pending.”
5 May 202610-QNet sales $2.74B (-4% y/y); Gross margin 37.1; Adjusted Operating EBITDA margin 20.7; Guidance: capex guided to ~6% of sales in 2026 vs 5.5% in 2025open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $2.74B | -4% y/y |
| Gross margin · Q1-2026 | 37.1% | |
| Adjusted Operating EBITDA margin · Q1-2026 | 20.7% | |
| Operating cash flow · Q1-2026 | $257M | +102% y/y |
Guidance
capex guided to ~6% of sales in 2026 vs 5.5% in 2025
No explicit revenue or margin guidance; capex guidance indicates increased investment; management tone is positive based on volume growth and productivity gains.
Risks flagged
Scent segment pricing pressure
“On a comparable currency neutral basis, Scent Segment Adjusted Operating EBITDA decreased 2% in 2026 compared to the prior year period as unfavorable net pricing more than offset volume increases.” · word for word
Divestiture execution risk
“Losses on business disposals were $7 million in the first quarter of 2026. The loss in 2026 was due to the SCL disposal group business divestiture.” · word for word
5 May 20268-K · 2.02Net sales $2.74B (-4% y/y); Adjusted operating EBITDA $568M; Adjusted EPS excluding amortization $1.25; Guidance: Sales guidance $10.5B-$10.8Bearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $2.74B | -4% y/y |
| Adjusted operating EBITDA · Q1-2026 | $568M | |
| Adjusted EPS excluding amortization · Q1-2026 | $1.25 | |
| Free cash flow · Q1-2026 | $92M |
Guidance
Sales guidance $10.5B-$10.8B
Reaffirmed full-year 2026 guidance, citing solid Q1 results and derisking of balance of year.
Risks flagged
Uncertain operating environment may impact future performance; Scent segment EBITDA declined due to unfavorable price to input cost.
“Scent adjusted operating EBITDA decreased (2)% as volume growth and productivity gains were more than offset by unfavorable price to input cost.”
18 Mar 2026DEF 14AIFF filed its 2026 proxy statement, disclosing 2025 compensation, governance updates, and a clawback of $606,280 due to an accounting restatementopen
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $10.90B | |
| Operating Loss · FY2025 | $-382M | |
| Adjusted Operating EBITDA · FY2025 | $2.10B | |
| Diluted EPS · FY2025 | $-1.41 | |
| Adjusted Diluted EPS · FY2025 | $2.52 | |
| Adjusted Diluted EPS ex Amortization · FY2025 | $4.20 | |
| Net Debt to Credit Adjusted EBITDA · FY2025 | $2.60 | |
| Share Repurchase Authorization · FY2025 | $500M | |
| Currency Neutral Sales Growth · FY2025 | 2.0% | |
| Currency Neutral Adjusted Operating EBITDA Growth · FY2025 | 7.0% |
Risks flagged
Accounting restatement risk
“Management identified certain adjustments that primarily relate to the understatement of income tax expense due to errors in the accounting for transfer pricing, the correction of deferred tax liabilities on goodwill recorded in purchase accounting, and other income tax entries that impacted prior interim and annual financial statements” · word for word
Goodwill impairment risk
“The 2025 Net Loss of $361 million reflects a goodwill impairment charge of $1.153 Billion”
Portfolio execution risk
“the Company commenced an evaluation of strategic alternatives for the Food Ingredients business” · word for word
27 Feb 202610-KNet sales $10.89B (-5% y/y); Gross profit $3.94B (-5% y/y); Gross margin 36.2; Guidance: Capital spending expected to be approximately 6% of sales in 2026open
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $10.89B | -5% y/y |
| Gross profit · FY2025 | $3.94B | -5% y/y |
| Gross margin · FY2025 | 36.2% | |
| Net income (loss) attributable to IFF shareholders · FY2025 | $-361M | -237% y/y |
| Operating cash flow · FY2025 | $850M | -21% y/y |
| Goodwill impairment · Food Ingredients · FY2025 | $1.15B | |
| Capital spending as % of sales (guidance) · FY2026 | 6.0% |
Guidance
Capital spending expected to be approximately 6% of sales in 2026
No explicit revenue or margin guidance; capex guidance provided; management tone appears positive based on volume growth and margin improvement.
Risks flagged
Goodwill impairment risk
“we determined that the carrying value of the Food Ingredients reporting unit exceeded its fair value and recorded an impairment charge of $1.153 billion.” · word for word
Divestiture execution risk
“We completed the divestiture of our Pharma Solutions disposal group ... on May 1, 2025 and we divested our nitrocellulose business ... on May 9, 2025.” · word for word
Raw material cost volatility
“Our products rely on both natural and synthetic ingredients.” · word for word
11 Feb 20268-K · 2.02Net sales $10.89B (-5% y/y); Adjusted operating EBITDA $2.09B (+7% y/y); Adjusted EPS excluding amortization $4.20earningsopen
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $10.89B | -5% y/y |
| Adjusted operating EBITDA · FY2025 | $2.09B | +7% y/y |
| Adjusted EPS excluding amortization · FY2025 | $4.20 | |
| Cash flow from operations · FY2025 | $850M | |
| Free cash flow · FY2025 | $256M | |
| Taste segment sales · Taste · FY2025 | $2.48B | +2% y/y |
| Health & Biosciences segment sales · Health & Biosciences · FY2025 | $2.28B | +4% y/y |
| Scent segment sales · Scent · FY2025 | $2.48B | +2% y/y |
| Food Ingredients segment sales · Food Ingredients · FY2025 | $3.28B | -3% y/y |
| Reported loss before taxes · FY2025 | $-412M |
Risks flagged
Macroeconomic uncertainty persists, potentially impacting demand.
“While macroeconomic uncertainty persists, we are encouraged by the strength of our pipeline” · word for word
Food Ingredients segment under pressure from Protein Solutions softness and low-margin business exit.
“Food Ingredients ... comparable currency neutral sales decreased (3)% as double-digit growth in Inclusions was offset primarily by softness in Protein Solutions as well as the proactive exit of low margin business”
4 Nov 20258-K · 2.02Sales $2.69B (-8% y/y); Income before taxes $56M; EPS $0.16earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2025 | $2.69B | -8% y/y |
| Income before taxes · Q3-2025 | $56M | |
| EPS · Q3-2025 | $0.16 | |
| Adjusted operating EBITDA · Q3-2025 | $519M | |
| Adjusted operating EBITDA margin · Q3-2025 | 19.3% | |
| EPS ex amortization · Q3-2025 | $1.05 | |
| Cash flows from operations (9 months) · 9M-2025 | $532M | |
| Free cash flow (9 months) · 9M-2025 | $126M |
Guidance
Reaffirms full year 2025 guidance despite 'more challenging operating environment'; margin expansion driven by productivity
Risks flagged
Tough operating environment, short-term pressures in Health & Biosciences and Food Ingredients, sales decline 8% reported
4 Nov 202510-QIFF reported Q3 2025 net sales of $2.694B (-8% reported, flat comparable currency neutral), gross margin +50bps, and completed divestitures of Pharma Solutions and Nitrocellulose.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Consolidated · Q3-2025 | $2.69B | -8% y/y |
| Gross margin · Consolidated · Q3-2025 | 36.5% | |
| Net income (loss) attributable to IFF shareholders · Consolidated · Q3-2025 | $40M | -31% y/y |
| Cash and cash equivalents · Consolidated · 2025-09-30 | $621M | |
| Free cash flow (operating) · Consolidated · 9M-2025 | $532M | -22% y/y |
Risks flagged
Goodwill impairment risk
“The impairment of goodwill was $1.153 billion in the first nine months of 2025 compared to $64 million in the 2024 period.” · word for word
Divestiture execution risk
“Loss on assets classified as held for sale was $108 million in Q3 2025 related to Soy Crush, Concentrates & Lecithin business.” · word for word
Leverage and debt covenant risk
“Our Revolving Credit Agreement states that from the effective date through September 30, 2025, our net debt to credit adjusted EBITDA ratio shall not exceed 4.00x, and shall not exceed 3.75x thereafter.”
International Flavors & Fragrances Inc. — questions
- What did International Flavors & Fragrances Inc. file recently?
- 12 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — IFF reported Q2 2026 results: sales +2% reported (+6% comparable currency neutral), gross margin +80bps, operating profit +11%, and announced $2.5B share repurchase authorization.
Every figure on this page comes from International Flavors & Fragrances Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.